Regulatory perspective on translating proteomic biomarkers to clinical diagnostics

► Overview of FDA regulation pathways on in vitro diagnostic tests. ► Overview of mass spectrometry technology and potential concerns for translation to clinical diagnostics. ► Regulatory requirements for premarket submissions and considerations applicable to proteomic assays.